Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
80 participants
INTERVENTIONAL
2022-04-15
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of Plane Warts With Topical and Oral Retinoids
NCT07012811
Intralesional Injection of Combined Digoxin and Furosemide Versus 5-Flurouracil in Plantar Warts
NCT05599971
Comparison of Five Treatments in Patients With Plantar Warts
NCT01059110
The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts
NCT03477448
A Cohort Study of Hyperthermia and Imiquimod for the Treatment of Flat Warts
NCT05146895
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Group (A): Patients will be treated with topical tazarotene gel 0.1%with a cotton tipped applicator on every lesion once daily at night.
* Group (B): Patients will be treated with topical 5- fluorouracil 5% cream applied once daily at night.
* Group (C): Patients will be treated with imiquimod cream 5% applied once daily at night.
* Group (D): Patients will be treated with petroleum jelly once daily at night.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tazarotene
20 patients of verruca plana receiving daily topical Tazarotene 0.1% gel at night
Tazarotene 0.1% Gel,Top
once daily topical application at night with a cotton tipped applicator on every lesion
Imiquimod
20 patients with verruca plana will be treated with imiquimod cream 5% applied once daily at night
Imiquimod
Imiquimod cream 5% applied once daily at night with a cotton tipped applicator applied once daily.
5- fluorouracil
20 patients with verruca plana will be treated with topical 5- fluorouracil 5% cream applied once daily at night
Fluorouracil Cream
5- Fluorouracil Cream 5% is applied once daily at night with a cotton tipped applicator
Petrolatum
20 patients with verruca plana will be treated with petroleum jelly once daily at night.
Petrolatum
applied once daily at night
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tazarotene 0.1% Gel,Top
once daily topical application at night with a cotton tipped applicator on every lesion
Imiquimod
Imiquimod cream 5% applied once daily at night with a cotton tipped applicator applied once daily.
Fluorouracil Cream
5- Fluorouracil Cream 5% is applied once daily at night with a cotton tipped applicator
Petrolatum
applied once daily at night
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \> 4 years.
* Both sexes.
* Patients with clinically and dermoscopically diagnosed plane warts.
* Subject is willing and able to follow all study instructions and to attend all study visits
Exclusion Criteria
* Pregnancy and lactation.
* Patients with epidermodysplasia verruciformis syndrome.
* Patients with eczematous skin disorders.
* Presence of any active infections e.g. herpes, tuberculosis.
* History of topical anti wart treatment within 4 weeks of recruitment to the study, and a 12-week period for systemic anti-wart treatment, or immunotherapy, or HPV vaccine in the last 24 weeks.
4 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zagazig University
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hagar Nofal
Lecturer, Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dermatology department, Zagazig University Hospitals, Faculty of Medicine, Zagazig University
Zagazig, Select Region, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Hodeib AAE, Al-Sharkawy BG, Hegab DS, Talaat RAZ. A comparative study of intralesional injection of Candida albicans antigen, bleomycin and 5-fluorouracil for treatment of plane warts. J Dermatolog Treat. 2021 Sep;32(6):663-668. doi: 10.1080/09546634.2019.1688236. Epub 2019 Nov 12.
Gladsjo JA, Alio Saenz AB, Bergman J, Kricorian G, Cunningham BB. 5% 5-Fluorouracil cream for treatment of verruca vulgaris in children. Pediatr Dermatol. 2009 May-Jun;26(3):279-85. doi: 10.1111/j.1525-1470.2008.00800.x.
Kim MB, Ko HC, Jang HS, Oh CK, Kwon KS. Treatment of flat warts with 5% imiquimod cream. J Eur Acad Dermatol Venereol. 2006 Nov;20(10):1349-50. doi: 10.1111/j.1468-3083.2006.01709.x. No abstract available.
Nofal A, Marei A, Ibrahim AM, Nofal E, Nabil M. Intralesional versus intramuscular bivalent human papillomavirus vaccine in the treatment of recalcitrant common warts. J Am Acad Dermatol. 2020 Jan;82(1):94-100. doi: 10.1016/j.jaad.2019.07.070. Epub 2019 Jul 29.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
9326/22-2-2022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.